NO20015259D0 - Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler - Google Patents

Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler

Info

Publication number
NO20015259D0
NO20015259D0 NO20015259A NO20015259A NO20015259D0 NO 20015259 D0 NO20015259 D0 NO 20015259D0 NO 20015259 A NO20015259 A NO 20015259A NO 20015259 A NO20015259 A NO 20015259A NO 20015259 D0 NO20015259 D0 NO 20015259D0
Authority
NO
Norway
Prior art keywords
obesity
preparation
substituted bicyclic
bicyclic heterocycles
hypercholesterolemic agents
Prior art date
Application number
NO20015259A
Other languages
English (en)
Other versions
NO320805B1 (no
NO20015259L (no
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Channaveerappa Bajji Ashok
Shivaramayya Kalchar
Ranga Madhavan Gurram
Ramanujam Rajagopalan
Chakrabarti Ranjan
Original Assignee
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Research Foundation filed Critical Reddy Research Foundation
Publication of NO20015259D0 publication Critical patent/NO20015259D0/no
Publication of NO20015259L publication Critical patent/NO20015259L/no
Publication of NO320805B1 publication Critical patent/NO320805B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
NO20015259A 1999-04-28 2001-10-26 Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem. NO320805B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN484MA1999 1999-04-28
PCT/IB2000/000501 WO2000066572A1 (en) 1999-04-28 2000-04-25 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

Publications (3)

Publication Number Publication Date
NO20015259D0 true NO20015259D0 (no) 2001-10-26
NO20015259L NO20015259L (no) 2001-11-15
NO320805B1 NO320805B1 (no) 2006-01-30

Family

ID=11095336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015259A NO320805B1 (no) 1999-04-28 2001-10-26 Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem.

Country Status (25)

Country Link
US (1) US7348426B1 (no)
EP (1) EP1175412A1 (no)
JP (1) JP2002543194A (no)
KR (1) KR100610578B1 (no)
CN (1) CN1353699A (no)
AU (1) AU781079B2 (no)
BG (1) BG106146A (no)
BR (1) BR0010139A (no)
CA (1) CA2371757A1 (no)
CZ (1) CZ20013832A3 (no)
EE (1) EE200100540A (no)
HR (1) HRP20010785A2 (no)
HU (1) HUP0600105A3 (no)
IL (1) IL146104A0 (no)
MX (1) MXPA01010916A (no)
NO (1) NO320805B1 (no)
NZ (1) NZ515284A (no)
PL (1) PL351987A1 (no)
RU (1) RU2278114C2 (no)
SK (1) SK15092001A3 (no)
TR (1) TR200103848T2 (no)
UA (1) UA73501C2 (no)
WO (1) WO2000066572A1 (no)
YU (1) YU75101A (no)
ZA (1) ZA200108733B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
WO2003018553A1 (en) * 2001-08-29 2003-03-06 Warner-Lambert Company Llc Oral antidiabetic agents
WO2003024944A1 (en) * 2001-09-20 2003-03-27 Dr. Reddy's Laboratories Ltd. An improved process for the preparation of bicyclic antidiabetic compounds
WO2003027084A1 (en) * 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
CN1589258A (zh) * 2001-10-16 2005-03-02 雷迪实验室有限公司 新的β－苯基－α－氧取代的丙酸衍生物,它的制备方法和它们制备药学上重要的化合物的应用
AU2003244514A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Limited Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
KR100841165B1 (ko) * 2002-04-30 2008-06-24 유씨비 파마, 에스.에이. 2,6-퀴놀리닐 및 2,6-나프틸 유도체, 이의 제조 방법 및ｖｌａ-4 억제제로서의 용도
WO2003099800A1 (en) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited An improved process for the preparation of bicyclic antidiabetic agents
AU2003276234B2 (en) * 2002-11-08 2007-04-19 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as PPAR agonists
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
DE202004002953U1 (de) * 2004-02-26 2004-04-29 Winkler, Wilhelm Verbindungseinheit
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
NZ563739A (en) 2005-06-09 2009-12-24 Ucb Pharma Sa 2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
RU2684779C2 (ru) * 2016-02-05 2019-04-15 АО "Институт химических наук им. А.Б. Бектурова" Применение производного бета-морфолинопропиоамидоксима в качестве противодиабетического средства
CN110092774B (zh) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 芳香丙酸类衍生物、及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
GB9027023D0 (en) * 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
JPH0912575A (ja) * 1995-06-28 1997-01-14 Sankyo Co Ltd ベンゾオキサジンおよびベンゾチアジン誘導体
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2260044A1 (en) 1996-07-12 1998-01-22 Stephen Alistair Smith Novel treatment of leptine resistance
US6265401B1 (en) * 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
RU2247722C2 (ru) * 1997-10-27 2005-03-10 Др. Редди`З Лабораториз Лимитед Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TR200103848T2 (tr) 2002-04-22
HUP0600105A3 (en) 2006-11-28
KR100610578B1 (ko) 2006-08-09
ZA200108733B (en) 2003-01-23
SK15092001A3 (sk) 2002-05-09
NZ515284A (en) 2004-12-24
JP2002543194A (ja) 2002-12-17
CZ20013832A3 (cs) 2002-04-17
PL351987A1 (en) 2003-07-14
CA2371757A1 (en) 2000-11-09
AU781079B2 (en) 2005-05-05
NO320805B1 (no) 2006-01-30
UA73501C2 (en) 2005-08-15
HUP0600105A2 (en) 2006-05-29
IL146104A0 (en) 2002-07-25
EE200100540A (et) 2002-12-16
NO20015259L (no) 2001-11-15
AU3983100A (en) 2000-11-17
CN1353699A (zh) 2002-06-12
WO2000066572A1 (en) 2000-11-09
YU75101A (sh) 2005-07-19
KR20010113891A (ko) 2001-12-28
MXPA01010916A (es) 2002-06-21
HRP20010785A2 (en) 2003-02-28
EP1175412A1 (en) 2002-01-30
RU2278114C2 (ru) 2006-06-20
BG106146A (bg) 2002-05-31
US7348426B1 (en) 2008-03-25
BR0010139A (pt) 2004-03-02

Similar Documents

Publication Publication Date Title
NO20015259L (no) Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler
PT1459751E (pt) (s,s)-reboxetina para tratar as enxaquecas
NO20040678L (no) Aminoalkyl-substituert aromatiske bicykliske forbindelser, fremgangsmate for deres fremstilling og deres anvendelse som legemidler.
NO20012058D0 (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
DE69923594D1 (de) Flammhemmende, mikroporöse materialien
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1110949T3 (da) EP4-receptorselektive agonister, som er anvendelige ved behandling af osteoporose
EE04527B1 (et) Aromaatsed heterotsüklilised ühendid, nende kasutamine ja meetodid nende valmistamiseks
NO20020684D0 (no) Aminopyrazolderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
DK1307457T3 (da) Azabicycliske forbindelser, deres fremstilling og deres anvendelse som medikamenter, især som antibakterielle midler
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
NO20014603L (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
DK1226188T3 (da) Fremgangsmåde til fremstilling af mannichaddukter, som indeholder polyisobutenphenol
NO20020314D0 (no) 2-arylimino-2,3-dihydrotiazoler og deres anvendelse som ligander for somatostatin-reseptorer
EE200300245A (et) Bensotiofeeni derivaadid, nende valmistamise meetod ja kasutamine
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20022834L (no) Zeolitt SSZ-50, fremgangsmåte for fremstilling og anvendelse av denne
DK1339685T3 (da) Biphenylcarboxamider, der er egnede som lipidsænkende midler
HK1052703A1 (en) Salts of bicyclic, n-acylated imidazo-3-amines andimidazo-5-amines.
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
IS6522A (is) Aðferð til framleiðslu á 5-sýanó-1-(4-flúorófenýl)-1,3-díhýdróísóbensófúrönum
NO971136D0 (no) Aminoalkyl- og acylaminoaklyleter, fremgangsmåte for fremstilling derav og anvendelse som bradykinin-reseptor antagonister
PT1165495E (pt) Derivados de resorcinol
NO20004271D0 (no) Benzylpiperazinyl- og benzylpiperidinyl etanonderivater, deres fremstilling og deres anvendelse som dopamin D4 reseptorantagonister
DK1098891T3 (da) Polycycliske thiazolidin-2-yliden-aminer, fremgangsmåde til fremstilling deraf og deres anvendelse som lægemidler